arrow_back Back Filing freshness 10-Q Q2 FY2027 SEC EDGAR

IRIDEX CORP

IRIX
$0.70 ▲ +0.01 (+0.72%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

IRIDEX CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $12.2M
Dividend Yield —
Revenue Growth -7.4% ↘
Op. Margin -8.2% ↘
ROIC -29.9% ↘
FCF / Share $0.01 ↗
Trailing P/E —
Price / Book 3.4x
FCF Yield 1.0%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 4, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.57M
↓ -7.4% —
Net Income Profit after all expenses
$-1.27M
↓ -27.4% —
Operating Margin Operating profit as % of sales
-8.2%
↓ -198.2% 17th
FCF / Share Free cash flow per share
$0.01
↑ +108.6% —
Long-Term Debt Long-term obligations
$1.00M
↓ -28.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
14
Returns ↓
8
Financial Health ↓
18
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters